Specific inflammasomes in complex diseases

Clinical Immunology

Volumn 147, Issue 3, 2013, Pages 223-228

  Masters, Seth L ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Autoinflammation; Inflammasome; Interleukin 1; NLRP3

Indexed keywords

CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; AIM2 PROTEIN, HUMAN; APOPTOSIS REGULATORY PROTEIN; CARRIER PROTEIN; NLRP1 PROTEIN, HUMAN; NLRP3 PROTEIN, HUMAN; NLRP6 PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ALLERGY; ALZHEIMER DISEASE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; COMORBIDITY; CYTOPENIA; GOUT; HUMAN; IMMUNE COMPLEX DISEASE; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; METABOLIC DISORDER; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRION DISEASE; PRIORITY JOURNAL; REVIEW; ANIMAL; ENTERITIS; GENETICS; IMMUNOLOGY; METABOLISM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ALZHEIMER DISEASE; ANIMALS; APOPTOSIS REGULATORY PROTEINS; ATHEROSCLEROSIS; CARRIER PROTEINS; DIABETES MELLITUS, TYPE 2; GOUT; HUMANS; INFLAMMASOMES; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-18; INTERLEUKIN-1BETA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; OBESITY;

EID: 84882285470     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.12.006     Document Type: Review

References (80)

1. H.M. Hoffman, et al., Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome, Nat. Genet. 29 (3) (2001) 301-305.
2. R. Goldbach-Mansky, et al., Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition, N. Engl. J. Med. 355 (6) (2006) 581-592.
3. O. Gross, et al., Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1, Immunity 36 (3) (2012) 388-400.
4. A. Fettelschoss, et al., Inflammasome activation and IL-1beta target IL-1alpha for secretion as opposed to surface expression, Proc. Natl. Acad. Sci. U. S. A. 108 (44) (2011) 18055-18060.
5. M. Boni-Schnetzler, M.Y. Donath, How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes, Br. J. Clin. Pharmacol. (2012).
6. R. Zhou, et al., Thioredoxin-interacting protein links oxidative stress to inflammasome activation, Nat. Immunol. 11 (2) (2010) 136-140.
7. S.L. Masters, et al., Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes, Nat. Immunol. 11 (10) (2010) 897-904.
8. C.M. Oslowski, et al., Thioredoxin-interacting protein mediates ER stress-induced beta cell death through initiation of the inflammasome, Cell Metab. 16 (2) (2012) 265-273.
9. A.G. Lerner, et al., IRE1alpha induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress, Cell Metab. 16 (2) (2012) 250-264.
10. B. Vandanmagsar, et al., The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance, Nat. Med. 17 (2) (2011) 179-188.
11. H. Wen, et al., Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling, Nat. Immunol. 12 (5) (2011) 408-415.
12. S. Normand, et al., Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury, Proc. Natl. Acad. Sci. U. S. A. 108 (23) (2011) 9601-9606.
13. E. Elinav, et al., NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis, Cell 145 (5) (2011) 745-757.
14. J. Henao-Mejia, et al., Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity, Nature 482 (7384) (2012) 179-185.
15. T. Niwa, et al., Interferon-gamma produced by bone marrowderived cells attenuates atherosclerotic lesion formation in LDLR-deficient mice, J. Atheroscler. Thromb. 11 (2) (2004) 79-87.
16. M.J. Nicklin, et al., Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene, J. Exp. Med. 191 (2) (2000) 303-312.
17. P. Duewell, et al., NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals, Nature 464 (7293) (2010) 1357-1361.
18. P. Menu, et al., Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome, Cell Death Dis. 2 (2011) e137.
19. J. Gage, et al., Caspase-1 deficiency decreases atherosclerosis in apolipoprotein E-nullmice, Can. J. Cardiol. 28 (2) (2012) 222-229.
20. F. Usui, et al., Critical role of caspase-1 in vascular inflammation and development of atherosclerosis in Western diet-fed apolipoprotein E-deficient mice, Biochem. Biophys. Res. Commun. 425 (2) (2012) 162-168.
21. P.M. Ridker, et al., Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), Am. Heart J. 162 (4) (2011) 597-605.
22. F. Martinon, et al., Gout-associated uric acid crystals activate the NALP3 inflammasome, Nature 440 (7081) (2006) 237-241.
23. A. So, et al., A pilot study of IL-1 inhibition by anakinra in acute gout, Arthritis Res. Ther. 9 (2) (2007) R28.
24. A. Halle, et al., The NALP3 inflammasome is involved in the innate immune response to amyloid-beta, Nat. Immunol. 9 (8) (2008) 857-865.
25. F. Meissner, K. Molawi, A. Zychlinsky, Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis, Proc. Natl. Acad. Sci. U. S. A. 107 (29) (2010) 13046-13050.
26. S.L. Doyle, et al., NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components, Nat. Med. 18 (5) (2012) 791-798.
27. V. Tarallo, et al., DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88, Cell 149 (4) (2012) 847-859.
28. I. Hafner-Bratkovic, et al., NLRP3 inflammasome activation in macrophage cell lines by prion protein fibrils as the source of IL-1beta and neuronal toxicity, Cell. Mol. Life Sci. 69 (24) (2012) 4215-4228.
29. F. Shi, et al., The NALP3 inflammasome is involved in neurotoxic prion peptide-induced microglial activation, J. Neuroinflammation 9 (2012) 73.
30. I.C. Allen, et al., The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer, J. Exp. Med. 207 (5) (2010) 1045-1056.
31. M.H. Zaki, M. Lamkanfi, T.D. Kanneganti, The Nlrp3 inflammasome: contributions to intestinal homeostasis, Trends Immunol. 32 (4) (2011) 171-179.
32. S.A. Hirota, et al., NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis, Inflamm. Bowel Dis. 17 (6) (2011) 1359-1372.
33. G.Y. Chen, et al., A functional role for Nlrp6 in intestinal inflammation and tumorigenesis, J. Immunol. 186 (12) (2011) 7187-7194.
34. B. Hu, et al., Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4, Proc. Natl. Acad. Sci. U. S. A. 107 (50) (2010) 21635-21640.
35. F.A. Carvalho, et al., Cytosolic flagellin receptor NLRC4 protects mice againstmucosal and systemic challenges, Mucosal Immunol. 5 (3) (2012) 288-298.
36. H. Takagi, et al., Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice, Scand. J. Gastroenterol. 38 (8) (2003) 837-844.
37. T. Kanai, et al., Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease, Gastroenterology 121 (4) (2001) 875-888.
38. T. Ten Hove, et al., Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice, Gastroenterology 121 (6) (2001) 1372-1379.
39. P.V. Sivakumar, et al., Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage, Gut 50 (6) (2002) 812-820.
40. M.H. Zaki, et al., IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation, J. Immunol. 185 (8) (2010) 4912-4920.
41. J. Ungerback, et al., Genetic variation and alterations of genes involved in NFkappaB/TNFAIP3- and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer, Carcinogenesis 33 (11) (2012) 2126-2134.
42. J.A. Lust, et al., Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component, Mayo Clin. Proc. 84 (2) (2009) 114-122.
43. D. Verma, et al., Inflammasome polymorphisms confer susceptibility to sporadic malignant melanoma, Pigment Cell Melanoma Res. 25 (4) (2012) 506-513.
44. M. Okamoto, et al., Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta, J. Biol. Chem. 285 (9) (2010) 6477-6488.
45. L. Feldmeyer, et al., The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes, Curr. Biol. 17 (13) (2007) 1140-1145.
46. M.T. Chow, et al., NLRP3 promotes inflammation-induced skin cancer but is dispensable for asbestos-induced mesothelioma, Immunol. Cell Biol. 90 (10) (2012) 983-986.
47. H. Watanabe, et al., Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity, J. Invest. Dermatol. 127 (8) (2007) 1956-1963.
48. F.S. Sutterwala, et al., Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1, Immunity 24 (3) (2006) 317-327.
49. I.C. Allen, et al., Analysis of NLRP3 in the development of allergic airway disease in mice, J. Immunol. 188 (6) (2012) 2884-2893.
50. A.G. Besnard, et al., NLRP3 inflammasome is required in murine asthma in the absence of aluminum adjuvant, Allergy 66 (8) (2011) 1047-1057.
51. X. Dai, et al., Mite allergen is a danger signal for the skin via activation of inflammasome in keratinocytes, J. Allergy Clin. Immunol. 127 (3) (2011) 806-814, (e1-4).
52. F. Feng, et al., Hyaluronan activation of the Nlrp3 inflammasome contributes to the development of airway hyperresponsiveness, Environ. Health Perspect. 120 (12) (2012) 1692-1698.
53. J.L. Ather, et al., Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice, J. Immunol. 187 (1) (2011) 64-73.
54. Y. Hitomi, et al., Associations of functional NLRP3 polymorphisms with susceptibility to food-induced anaphylaxis and aspirin-induced asthma, J. Allergy Clin. Immunol. 124 (4) (2009) 779-785, (e6).
55. F. Macaluso, et al., Polymorphisms in NACHT-LRR (NLR) genes in atopic dermatitis, Exp. Dermatol. 16 (8) (2007) 692-698.
56. J.C. Arthur, et al., Cutting edge: NLRP12 controls dendritic and myeloid cell migration to affect contact hypersensitivity, J. Immunol. 185 (8) (2010) 4515-4519.
57. Y. Dombrowski, et al., Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions, Sci. Transl. Med. 3 (82) (2011) 82ra38.
58. Y. Dombrowski, et al., Honey bee (Apis mellifera) venominduces AIM2 inflammasome activation in human keratinocytes, Allergy 67 (11) (2012) 1400-1407.
59. Y. Jin, et al., NALP1 in vitiligo-associated multiple autoimmune disease, N. Engl. J. Med. 356 (12) (2007) 1216-1225.
60. A. Pontillo, et al., Polymorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus, Autoimmunity 45 (4) (2012) 271-278.
61. J. Sui, et al., NLRP1 gene polymorphism influences gene transcription and is a risk factor for rheumatoid arthritis in Han Chinese, Arthritis Rheum. 64 (3) (2012) 647-654.
62. A. Pontillo, et al., The missense variation Q705K in CIAS1/ NALP3/NLRP3 gene and an NLRP1 haplotype are associated with celiac disease, Am. J. Gastroenterol. 106 (3) (2011) 539-544.
63. P. Dieude, et al., NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis, Ann. Rheum. Dis. 70 (4) (2011) 668-674.
64. M. Zurawek, et al., A coding variant in NLRP1 is associated with autoimmune Addison's disease, Hum. Immunol. 71 (5) (2010) 530-534.
65. N.F. Magitta, et al., A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes, Genes Immun. 10 (2) (2009) 120-124.
66. P.A. Nigrovic, et al., Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series, Arthritis Rheum. 63 (2) (2011) 545-555.
67. A. Gul, et al., Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study, Ann. Rheum. Dis. 71 (4) (2012) 563-566.
68. T.G. Day, et al., Autoinflammatory genes and susceptibility to psoriatic juvenile idiopathic arthritis, Arthritis Rheum. 58 (7) (2008) 2142-2146.
69. M. Shimizu, et al., Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis, Rheumatology (Oxford) 49 (9) (2010) 1645-1653.
70. K. Luotola, et al., Association of variation in the interleukin-1 gene family with diabetes and glucose homeostasis, J. Clin. Endocrinol. Metab. 94 (11) (2009) 4575-4583.
71. W. Koch, et al., Interleukin 18 gene variation and risk of acute myocardial infarction, Cytokine 56 (3) (2011) 786-791.
72. F. Gianfagna, et al., A systematic review of meta-analyses on gene polymorphisms and gastric cancer risk, Curr. Genomics 9 (6) (2008) 361-374.
73. M.R. Haghshenas, et al., IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers, J. Gastroenterol. Hepatol. 24 (6) (2009) 1119-1122.
74. D. Zeyrek, et al., Association of interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in Turkish children with atopic asthma, Allergy Asthma Proc. 29 (5) (2008) 468-474.
75. Y. Ma, et al., Interleukin-18 promoter polymorphism and asthma risk: a meta-analysis, Mol. Biol. Rep. 39 (2) (2012) 1371-1376.
76. N. Ruperto, et al., A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features, Arthritis Rheum. 64 (2) (2012) 557-567.
77. C.J. Stock, et al., Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritis, Genes Immun. 9 (4) (2008) 349-357.
78. Y.J. Lee, et al., Interleukin-18 promoter polymorphisms in patients with Behcet's disease, Hum. Immunol. 67 (10) (2006) 812-818.
79. W.C. Jang, et al., Interleukin-18 gene polymorphisms in Korean patients with Behcet's disease, Clin. Exp. Rheumatol. 23 (4 Suppl. 38) (2005) S59-S63.
80. S.L. Masters, et al., NLRP1 Inflammasome Activation Induces Pyroptosis of Hematopoietic Progenitor Cells, Immunity 37 (6) (2012) 1009-1023.